Maxrets Ventures Past Earnings Performance
Past criteria checks 0/6
Maxrets Ventures has been growing earnings at an average annual rate of 14.5%, while the Pharmaceuticals industry saw earnings declining at 5.2% annually.
Key information
14.5%
Earnings growth rate
14.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 14.1% |
| Revenue growth rate | n/a |
| Return on equity | -2,515.8% |
| Net Margin | n/a |
| Last Earnings Update | 31 Oct 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Maxrets Ventures makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Oct 23 | 0 | 0 | 0 | 0 |
| 31 Oct 22 | 0 | -1 | 1 | 0 |
| 31 Jul 22 | 0 | -1 | 1 | 0 |
| 30 Apr 22 | 0 | -1 | 1 | 0 |
| 31 Jan 22 | 0 | 0 | 0 | 0 |
| 31 Oct 21 | 0 | 0 | 0 | 0 |
| 30 Apr 21 | 0 | 0 | 0 | 0 |
| 31 Jan 21 | 0 | 0 | 0 | 0 |
Quality Earnings: MAX is currently unprofitable.
Growing Profit Margin: MAX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if MAX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare MAX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MAX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10.2%).
Return on Equity
High ROE: MAX has a negative Return on Equity (-2515.79%), as it is currently unprofitable.